Why Is IONIS PHARMACEUTICAL (IONS) Stock Down Today?

IONS stock is down 7.43% at $47.62 as of the latest trade. The decline follows a price target cut by Guggenheim, which lowered its target for Ionis Pharmaceuticals to $80 from $89. This adjustment reflects concerns over the company’s sales outlook. The stock opened with a small gap up but quickly reversed course, hitting a session low of $47.57 before stabilizing slightly.

What Happened

Guggenheim’s revised price target signaled a shift in analyst sentiment, contributing to the stock’s downward momentum. The firm cited a cautious view of near-term sales performance as the reason for the downgrade. Meanwhile, other analysts have also adjusted their expectations. Barclays and Morgan Stanley each reduced their price targets to $85 and $104 respectively, while Goldman Sachs cut its target to $56 and maintained a neutral stance. These changes suggest a broad recalibration of expectations for Ionis Pharmaceuticals despite continued long-term optimism from some institutions.

Recent insider activity includes mixed signals. A director, Hayden Michael R, made a purchase on July 30, while others, including Diaz Allene M and Holly B. Kordasiewicz, sold shares on July 7. Over the past 90 days, insiders have sold $14.0 million worth of stock compared to $1.1 million in purchases. The most recent filing was on July 31.

What The Data Shows

The stock has fallen 17.8% over the last eight sessions, from $58.19 to $47.86. It is currently trading near its 52-week low of $50.01. The session has seen 2.1 million shares traded, or 0.8 times the 3-month average. The stock hit a fresh 52-week low on September 15, marking the third such instance. The company remains unprofitable with a TTM net margin of -64.7% and a revenue decline of 7.4% year-to-date.

What To Watch

Investors should monitor the company’s upcoming earnings report if scheduled. In the absence of an announced date, tracking the breadth of analyst coverage and any further price target adjustments will be key.